Alopecia Epidemiology Forecast 2025-2034

The absence or loss of hair in a region where it should be present is known as alopecia. It can be localized or diffuse, temporary or permanent. In 2019, there were over 3000 diagnoses of alopecia. The alopecia epidemiology forecast suggests that nonscarring type of alopecia is more common (73%), while scarring alopecia is less common (at 27%).

Alopecia Epidemiology Forecast Report Coverage

The “Alopecia Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of Alopecia. It projects the future incidence and prevalence rates of alopecia across various populations. The study covers age, gender, and type as major determinants of the alopecia population. The report highlights patterns in the prevalence of alopecia over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the alopecia epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Alopecia Understanding: Disease Overview

Alopecia is a disorder that affects the scalp and other areas of the body and causes hair loss, either temporary or permanent. It arises due to numerous circumstances, including heredity, autoimmune illnesses, hormonal changes, or stress. The most prevalent kind is alopecia areata, an autoimmune disease in which hair follicles are attacked by the immune system, resulting in patchy hair loss. Other types include telogen effluvium (excessive shedding brought on by sickness or stress) and androgenetic alopecia (pattern baldness). Although alopecia is not fatal, it can have a major negative influence on a person's emotional health and sense of self.

Alopecia Epidemiology Perspective

The alopecia epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for alopecia by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for alopecia and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to the study and statistics, androgenetic alopecia accounted for 37.7% of all cases of nonscarring alopecia, followed by alopecia areata wih 18.2% and telogen effluvium with 11.3%.
• The study also indicated that Scarring Alopecia included 10.8% cases for Frontal fibrosing alopecia, Lichen planopilaris 7.6% cases and 2.8% cases of folliculitis decalvans. The frequency of other alopecia types includes less than 2% cases globally.
• According to worldwide data, around 25% of patients experience discomfort and itching in the affected area; in contrast, FFA type alopecia is asymptomatic.
• Human hair can be divided into two categories: terminal hair and vellus hair. Terminal hair has a dynamic lower segment and a fixed top part. Anagen (expanding, 85%-90%), catagen (involuting, < 5%), and telogen (resting, 5%-10%) phases are the follicular cycles that the lower segment goes through. The anagen phase lasts between two and seven years on average. After then, the hair follicle moves into the catagen phase, which is the cycle's shortest phase and lasts roughly two to three weeks, followed by the telogen phase, which lasts two to four months. Hair length is determined by the length of anagen. When diagnosing and treating alopecia, these factors are considered.

Country-wise Alopecia Epidemiology

The alopecia epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of alopecia varies between countries owing to the differences in factors such as certain genetic and biological factors, natural environmental factors, dietary habits, pollution, and others. According to a study conducted by the Asian Journal of Research in Dermatological Science, 24595 patients with a diagnosis of hair loss had their data examined. The most frequent cause of hair loss was telogen effluvium (TE) (40.70%), which was followed by alopecia areata (AA) (12.81%), male pattern hair loss (MPHL) (7.49%), and female pattern hair loss (FPHL) (22.09%). Most cases were female, and the majority were between the ages of 12 and 39.

Alopecia: Treatment Overview

The goal of treating alopecia is to promote hair growth and stop more loss, depending on the condition's form and underlying cause. Common methods include oral drugs like finasteride for pattern baldness, corticosteroid injections for autoimmune-related hair loss, and topical therapies like minoxidil. To encourage hair regeneration, light therapy and platelet-rich plasma (PRP) therapy are frequently utilized. In extreme situations, scalp micropigmentation or hair transplant surgery could be explored for aesthetic enhancement. Stress reduction and lifestyle changes can also aid in the condition's management.

Key Questions Answered

• What are the key findings of alopecia epidemiology in the 8 major markets?
• What will be the total number of patients with alopecia across the 8 major markets during the forecast period?
• What was the country-wise prevalence of alopecia in the 8 major markets in the historical period?
• Which country will have the highest number of alopecia patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of alopecia during the forecast period of 2025-2034?
• What are the currently available treatments for alopecia?
• What are the disease risks, signs, symptoms, and unmet needs of alopecia?

This product will be delivered within 3-5 business days.